$14.38
-0.28 (-1.91%)
Open$14.60
Previous Close$14.66
Day High$14.67
Day Low$14.10
52W High$15.31
52W Low$2.16
Volume—
Avg Volume1.22M
Market Cap75.17M
P/E Ratio—
EPS$-1.60
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-3.8% upside
Current
$14.38
$14.38
Target
$13.83
$13.83
$9.36
$13.83 avg
$17.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 796.6K | 116.64M | 118.58M |
| Net Income | -8,336,243 | -21,434,773 | -22,545,743 |
| Profit Margin | -1,046.4% | -18.4% | -19.0% |
| EBITDA | -10,283,876 | -23,823,087 | -23,688,809 |
| Free Cash Flow | — | -12,084,786 | -12,382,292 |
| Rev Growth | — | -8.2% | -9.4% |
| Debt/Equity | — | 0.42 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |